- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06172296
- Procès original
Dinutuximab avec chimiothérapie, chirurgie et transplantation de cellules souches pour le traitement des enfants atteints d'un neuroblastome à haut risque nouvellement diagnostiqué
Une étude de phase 3 sur le dinutuximab ajouté à la thérapie multimodale intensive pour les enfants atteints d'un neuroblastome à haut risque nouvellement diagnostiqué
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
- Médicament: Carboplatin
- Médicament: Cyclophosphamide
- Médicament: Cisplatin
- Procédure: Bone Marrow Biopsy
- Médicament: Doxorubicin
- Médicament: Vincristine
- Procédure: Magnetic Resonance Imaging
- Procédure: Echocardiography Test
- Procédure: Multigated Acquisition Scan
- Procédure: Bone Marrow Aspiration
- Médicament: Etoposide
- Procédure: Computed Tomography
- Médicament: Topotecan
- Radiation: Radiation Therapy
- Procédure: Biospecimen Collection
- Autre: Survey Administration
- Médicament: Melphalan
- Médicament: Irinotecan
- Médicament: Thiotepa
- Biologique: Dinutuximab
- Procédure: FDG-Positron Emission Tomography and Computed Tomography Scan
- Procédure: Hematopoietic Cell Transplantation
- Médicament: Isotretinoin
- Procédure: Leukapheresis
- Procédure: Radionuclide Imaging
- Médicament: Temozolomide
- Procédure: Tumor Resection
Description détaillée
PRIMARY OBJECTIVE:
I. To determine if the event-free survival (EFS) of patients with newly diagnosed high-risk neuroblastoma assigned to early chemoimmunotherapy during Induction differs from that of patients who are not assigned to treatment that includes early chemoimmunotherapy.
SECONDARY OBJECTIVES:
I. To determine if early chemoimmunotherapy during Induction therapy improves end of Induction (EOI) response rates and overall survival (OS) for patients with newly diagnosed high-risk neuroblastoma.
II. To determine response rates, EFS, and OS following an Extended Induction regimen with chemoimmunotherapy in patients with progressive disease or a poor response to Induction therapy.
III. To compare the toxicities experienced by patients treated with chemoimmunotherapy during Induction versus those experienced by patients treated with standard Induction and to describe toxicities experienced during Extended Induction.
IV. To determine GD2 expression on tumor tissue and tumor cells in bone marrow and assess for associations with response and outcome.
EXPLORATORY OBJECTIVES:
I. To describe the association between tumor and host factors and outcomes in patients receiving protocol therapy.
II. To evaluate circulating biomarkers and markers of minimal residual disease at baseline and during therapy, and assess for associations with response and outcome.
III. To compare patterns of failure between patients treated with and without dinutuximab during induction.
IV. To determine the effect of telomere maintenance mechanisms on end of Induction response rates, EFS, and OS.
V. To explore the impact of high-risk neuroblastoma (HRNBL) and its therapy, including the addition of dinutuximab to Induction chemotherapy, on functional and quality of life outcomes in patients with HRNBL, as measured by caregiver (parent/legal guardian) and patient questionnaires.
VI. To describe the adequacy of diagnostic biopsy specimens, including those obtained by percutaneous core needle biopsy.
VII. To explore the associations between family-reported adverse social determinants of health and both clinical outcomes and biology.
VIII. To develop and validate deep learning predictors of Induction response based on diagnostic MIBG scans. (Imaging Objective) IX. To compare institutional versus central determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and poor end of induction response (PEIR) and good end of induction response (GEIR) determination. (Imaging Objective) X. To describe late toxicities (including impaired organ function, neuropsychiatric toxicity, and incidence of secondary malignancy) in patients treated with dinutuximab during Induction or Extended Induction to late toxicities in patients who have not received dinutuximab during these phases of therapy.
XI. To evaluate whether reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts.
XII. To compare post-transplant complications between treatment arms, and assess for associations with outcome.
XIII. To assess for associations between EOI response (including good end of Induction response [GEIR] and poor end of Induction response [PEIR]) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS).
XIV. To describe and compare the changes in image-defined risk factors (IDRFs) between patients treated with and without dinutuximab during Induction and associate with surgical outcomes and local failure rates following primary tumor resection.
XV. To bank serial samples of blood, bone marrow, and tumor tissue for future research.
OUTLINE: Patients receive Induction cycle 1 and are then randomized to 1 of 2 treatment arms.
INDUCTION CYCLE 1: Patients receive cyclophosphamide intravenously (IV) over 30 minutes and topotecan IV over 30 minutes on days 1-5 in the absence of unacceptable toxicity.
ARM A:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes and topotecan IV over 30 minutes on days 1-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients then receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide orally (PO), via nasogastric tube (NG), or via gastric tube (G-tube) on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous hematopoietic stem cell transplantations (HSCTs) during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion, patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2. Patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO twice daily (BID) on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, echocardiogram (ECHO) or multigated acquisition scan (MUGA), bone marrow aspiration and/or biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), iodine-123 meta-iodobenzylguanidine (I-MIBG) scan and possible fluorodeoxyglucose position emission tomography (FDG-PET) scan throughout the study.
ARM B:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes, topotecan IV over 30 minutes on days 1-5, and dinutuximab IV over 10 hours on days 2-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 and dinutuximab IV over 10 hours on days 2-5 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2, and dinutuximab IV over 10 hours on days 2-5 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide PO, via NG tube, or via G-tube on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous HSCTs during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2, patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO BID on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, ECHO or MUGA, bone marrow aspiration and/or biopsy, CT scan, MRI, I-MIBG scan and possible FDG-PET scan throughout the study.
After completion of study treatment, patients are followed up at 3, 6, 9,12, 15, 18, 24, 30, 36, 42, 48, 54, and 60 months and then periodically for up to 10 years from enrollment.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
New South Wales
-
Randwick, New South Wales, Australie, 2031
- Recrutement
- Sydney Children's Hospital
-
Chercheur principal:
- Draga Barbaric
-
Contact:
- Site Public Contact
- Numéro de téléphone: (02) 9382-1721
-
Westmead, New South Wales, Australie, 2145
- Recrutement
- The Children's Hospital at Westmead
-
Contact:
- Site Public Contact
- Numéro de téléphone: 61-2-9845 1400
-
Chercheur principal:
- Bhavna Padhye
-
-
Queensland
-
South Brisbane, Queensland, Australie, 4101
- Recrutement
- Queensland Children's Hospital
-
Chercheur principal:
- Steven A. Foresto
-
Contact:
- Site Public Contact
- Numéro de téléphone: 61 7 3068 1111
-
-
Victoria
-
Parkville, Victoria, Australie, 3052
- Recrutement
- Royal Children's Hospital
-
Chercheur principal:
- Martin A. Campbell
-
Contact:
- Site Public Contact
- Numéro de téléphone: 61 3 9345 5656
- E-mail: Jordan.Hansford@rch.org.au
-
-
Western Australia
-
Perth, Western Australia, Australie, 6009
- Recrutement
- Perth Children's Hospital
-
Contact:
- Site Public Contact
- E-mail: helpdesk@childrensoncologygroup.org
-
Chercheur principal:
- Michelle Ng
-
-
-
-
-
Québec, Canada, G1V 4G2
- Recrutement
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
Chercheur principal:
- Bruno Michon
-
Contact:
- Site Public Contact
- Numéro de téléphone: 418-525-4444
- E-mail: rechclinique@crchudequebec.ulaval.ca
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Recrutement
- Alberta Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 403-220-6898
- E-mail: research4kids@ucalgary.ca
-
Chercheur principal:
- Victor A. Lewis
-
Edmonton, Alberta, Canada, T6G 2B7
- Recrutement
- University of Alberta Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 780-407-8798
- E-mail: pedsoncologyresearch@ahs.ca
-
Chercheur principal:
- Sarah J. McKillop
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- Recrutement
- British Columbia Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 6477 604-875-2345
-
Chercheur principal:
- Rebecca J. Deyell
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- Recrutement
- CancerCare Manitoba
-
Contact:
- Site Public Contact
- Numéro de téléphone: 866-561-1026
- E-mail: ctu_web@cancercare.mb.ca
-
Chercheur principal:
- Stephanie M. Villeneuve
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Recrutement
- Janeway Child Health Centre
-
Chercheur principal:
- Lisa A. Goodyear
-
Contact:
- Site Public Contact
- Numéro de téléphone: 709-777-8727
- E-mail: beverlyj.mitchell@easternhealth.ca
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- Recrutement
- IWK Health Centre
-
Contact:
- Site Public Contact
- Numéro de téléphone: 902-470-8520
- E-mail: Research@iwk.nshealth.ca
-
Chercheur principal:
- Chelsea Ash
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- Recrutement
- McMaster Children's Hospital at Hamilton Health Sciences
-
Contact:
- Site Public Contact
- Numéro de téléphone: 905-521-2100
-
Chercheur principal:
- Uma H. Athale
-
London, Ontario, Canada, N6A 5W9
- Recrutement
- Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 519-685-8306
-
Chercheur principal:
- Shayna M. Zelcer
-
Ottawa, Ontario, Canada, K1H 8L1
- Recrutement
- Children's Hospital of Eastern Ontario
-
Contact:
- Site Public Contact
- Numéro de téléphone: 613-737-7600
-
Chercheur principal:
- Donna L. Johnston
-
Toronto, Ontario, Canada, M5G 1X8
- Recrutement
- Hospital for Sick Children
-
Contact:
- Site Public Contact
- Numéro de téléphone: 416-813-7654
- E-mail: ask.CRS@sickkids.ca
-
Chercheur principal:
- Daniel A. Morgenstern
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- Recrutement
- The Montreal Children's Hospital of the MUHC
-
Contact:
- Site Public Contact
- Numéro de téléphone: 514-412-4445
- E-mail: info@thechildren.com
-
Chercheur principal:
- Stephanie Mourad
-
Montreal, Quebec, Canada, H3T 1C5
- Recrutement
- Centre Hospitalier Universitaire Sainte-Justine
-
Chercheur principal:
- Monia Marzouki
-
Contact:
- Site Public Contact
- Numéro de téléphone: 514-345-4931
- E-mail: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Recrutement
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Contact:
- Site Public Contact
- Numéro de téléphone: 819-820-6480
- E-mail: crcinformation.chus@ssss.gouv.qc.ca
-
Chercheur principal:
- Stephanie Vairy
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 0W8
- Recrutement
- Jim Pattison Children's Hospital
-
Chercheur principal:
- Kathleen Felton
-
Contact:
- Site Public Contact
- Numéro de téléphone: 306-655-3544
- E-mail: Jessica.Marien@saskhealthauthority.ca
-
-
-
-
Auckland
-
Grafton, Auckland, Nouvelle-Zélande, 1145
- Recrutement
- Starship Children's Hospital
-
Chercheur principal:
- Andrew C. Wood
-
Contact:
- Site Public Contact
- Numéro de téléphone: 0800 728 436
-
-
-
-
-
San Juan, Porto Rico, 00926
- Recrutement
- University Pediatric Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 787-474-0333
-
Chercheur principal:
- Maria E. Echevarria
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35233
- Recrutement
- Children's Hospital of Alabama
-
Contact:
- Site Public Contact
- Numéro de téléphone: 205-638-9285
- E-mail: oncologyresearch@peds.uab.edu
-
Chercheur principal:
- Elizabeth D. Alva
-
Mobile, Alabama, États-Unis, 36604
- Recrutement
- USA Health Strada Patient Care Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-388-8721
-
Chercheur principal:
- Hamayun Imran
-
-
Arizona
-
Mesa, Arizona, États-Unis, 85202
- Recrutement
- Banner Children's at Desert
-
Contact:
- Site Public Contact
- Numéro de téléphone: 480-412-3100
-
Chercheur principal:
- Joseph C. Torkildson
-
Phoenix, Arizona, États-Unis, 85016
- Recrutement
- Phoenix Childrens Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 602-546-0920
-
Chercheur principal:
- Alok K. Kothari
-
Tucson, Arizona, États-Unis, 85719
- Recrutement
- Banner University Medical Center - Tucson
-
Contact:
- Site Public Contact
- E-mail: UACC-IIT@uacc.arizona.edu
-
Chercheur principal:
- Monica M. Davini
-
-
Arkansas
-
Little Rock, Arkansas, États-Unis, 72202-3591
- Recrutement
- Arkansas Children's Hospital
-
Chercheur principal:
- Michael W. Bishop
-
Contact:
- Site Public Contact
- Numéro de téléphone: 501-364-7373
-
-
California
-
Downey, California, États-Unis, 90242
- Recrutement
- Kaiser Permanente Downey Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 626-564-3455
-
Chercheur principal:
- Robert M. Cooper
-
Duarte, California, États-Unis, 91010
- Recrutement
- City of Hope Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-826-4673
- E-mail: becomingapatient@coh.org
-
Chercheur principal:
- Hung C. Tran
-
Loma Linda, California, États-Unis, 92354
- Recrutement
- Loma Linda University Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 909-558-4050
-
Chercheur principal:
- Albert Kheradpour
-
Long Beach, California, États-Unis, 90806
- Recrutement
- Miller Children's and Women's Hospital Long Beach
-
Contact:
- Site Public Contact
- Numéro de téléphone: 562-933-5600
-
Chercheur principal:
- Jacqueline N. Casillas
-
Los Angeles, California, États-Unis, 90027
- Recrutement
- Children's Hospital Los Angeles
-
Contact:
- Site Public Contact
- Numéro de téléphone: 323-361-4110
-
Chercheur principal:
- Araz Marachelian
-
Los Angeles, California, États-Unis, 90048
- Recrutement
- Cedars-Sinai Medical Center
-
Chercheur principal:
- Fataneh (Fae) Majlessipour
-
Contact:
- Site Public Contact
- Numéro de téléphone: 310-423-2133
- E-mail: Cancer.trial.info@cshs.org
-
Los Angeles, California, États-Unis, 90095
- Recrutement
- Mattel Children's Hospital UCLA
-
Contact:
- Site Public Contact
- Numéro de téléphone: 310-825-6708
-
Chercheur principal:
- Satiro N. De Oliveira
-
Madera, California, États-Unis, 93636
- Recrutement
- Valley Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 559-353-3000
- E-mail: Research@valleychildrens.org
-
Chercheur principal:
- Ruetima Titapiwatanakun
-
Oakland, California, États-Unis, 94611
- Recrutement
- Kaiser Permanente-Oakland
-
Contact:
- Site Public Contact
- Numéro de téléphone: 877-642-4691
- E-mail: Kpoct@kp.org
-
Chercheur principal:
- Aarati V. Rao
-
Oakland, California, États-Unis, 94609
- Recrutement
- UCSF Benioff Children's Hospital Oakland
-
Chercheur principal:
- Jennifer G. Michlitsch
-
Contact:
- Site Public Contact
- Numéro de téléphone: 510-428-3264
- E-mail: PedOncRschOAK@ucsf.edu
-
Orange, California, États-Unis, 92868
- Recrutement
- Children's Hospital of Orange County
-
Contact:
- Site Public Contact
- Numéro de téléphone: 714-509-8646
- E-mail: oncresearch@choc.org
-
Chercheur principal:
- Elyssa M. Rubin
-
Palo Alto, California, États-Unis, 94304
- Recrutement
- Lucile Packard Children's Hospital Stanford University
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-694-0012
- E-mail: ccto-office@stanford.edu
-
Chercheur principal:
- Jay Michael S. Balagtas
-
Sacramento, California, États-Unis, 95817
- Recrutement
- University of California Davis Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 916-734-3089
-
Chercheur principal:
- Marcio H. Malogolowkin
-
Sacramento, California, États-Unis, 95816
- Recrutement
- Sutter Medical Center Sacramento
-
Contact:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Chercheur principal:
- Sandra Baril
-
San Diego, California, États-Unis, 92123
- Recrutement
- Rady Children's Hospital - San Diego
-
Contact:
- Site Public Contact
- Numéro de téléphone: 858-966-5934
-
Chercheur principal:
- William D. Roberts
-
San Francisco, California, États-Unis, 94158
- Recrutement
- UCSF Medical Center-Mission Bay
-
Contact:
- Site Public Contact
- Numéro de téléphone: 877-827-3222
- E-mail: cancertrials@ucsf.edu
-
Chercheur principal:
- Arun A. Rangaswami
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Recrutement
- Children's Hospital Colorado
-
Chercheur principal:
- Navin R. Pinto
-
Contact:
- Site Public Contact
- Numéro de téléphone: 303-764-5056
- E-mail: josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford, Connecticut, États-Unis, 06106
- Recrutement
- Connecticut Children's Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 860-545-9981
-
Chercheur principal:
- Michael S. Isakoff
-
New Haven, Connecticut, États-Unis, 06520
- Recrutement
- Yale University
-
Contact:
- Site Public Contact
- Numéro de téléphone: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Chercheur principal:
- Farzana Pashankar
-
-
Delaware
-
Wilmington, Delaware, États-Unis, 19803
- Recrutement
- Alfred I duPont Hospital for Children
-
Contact:
- Site Public Contact
- Numéro de téléphone: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Chercheur principal:
- Sridhi Patel
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20010
- Recrutement
- Children's National Medical Center
-
Chercheur principal:
- Jeffrey S. Dome
-
Contact:
- Site Public Contact
- Numéro de téléphone: 202-476-2800
- E-mail: OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Fort Lauderdale, Florida, États-Unis, 33316
- Recrutement
- Broward Health Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Chercheur principal:
- Hector M. Rodriguez-Cortes
-
Fort Myers, Florida, États-Unis, 33908
- Recrutement
- Golisano Children's Hospital of Southwest Florida
-
Contact:
- Site Public Contact
- Numéro de téléphone: 239-343-5333
- E-mail: molly.arnstrom@leehealth.org
-
Chercheur principal:
- Emad K. Salman
-
Gainesville, Florida, États-Unis, 32610
- Recrutement
- UF Health Cancer Institute - Gainesville
-
Contact:
- Site Public Contact
- Numéro de téléphone: 352-273-8010
- E-mail: cancer-center@ufl.edu
-
Chercheur principal:
- Brian Stover
-
Hollywood, Florida, États-Unis, 33021
- Recrutement
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 954-265-1847
- E-mail: OHR@mhs.net
-
Chercheur principal:
- Iftikhar Hanif
-
Jacksonville, Florida, États-Unis, 32207
- Recrutement
- Nemours Children's Clinic-Jacksonville
-
Contact:
- Site Public Contact
- Numéro de téléphone: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Chercheur principal:
- Sridhi Patel
-
Miami, Florida, États-Unis, 33155
- Recrutement
- Nicklaus Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 888-624-2778
-
Chercheur principal:
- Ziad A. Khatib
-
Miami, Florida, États-Unis, 33136
- Recrutement
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 305-243-2647
-
Chercheur principal:
- Meghan McCormick
-
Orlando, Florida, États-Unis, 32806
- Recrutement
- Arnold Palmer Hospital for Children
-
Contact:
- Site Public Contact
- Numéro de téléphone: 321-841-5357
- E-mail: Jennifer.spinelli@orlandohealth.com
-
Chercheur principal:
- Zhongbo Hu
-
Orlando, Florida, États-Unis, 32827
- Recrutement
- Nemours Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Chercheur principal:
- Sridhi Patel
-
Orlando, Florida, États-Unis, 32803
- Recrutement
- AdventHealth Orlando
-
Contact:
- Site Public Contact
- Numéro de téléphone: 407-303-2090
- E-mail: FH.Cancer.Research@flhosp.org
-
Chercheur principal:
- Fouad M. Hajjar
-
St. Petersburg, Florida, États-Unis, 33701
- Recrutement
- Johns Hopkins All Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 727-767-4784
- E-mail: Ashley.Repp@jhmi.edu
-
Chercheur principal:
- Jennifer B. Dean
-
West Palm Beach, Florida, États-Unis, 33407
- Recrutement
- Saint Mary's Medical Center
-
Chercheur principal:
- Matthew D. Ramirez
-
Contact:
- Site Public Contact
- Numéro de téléphone: 561-822-4745
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30329
- Recrutement
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Chercheur principal:
- William T. Cash
-
Contact:
- Site Public Contact
- Numéro de téléphone: 404-785-0232
- E-mail: Olivia.Floyd@choa.org
-
Savannah, Georgia, États-Unis, 31404
- Recrutement
- Memorial Health University Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 912-350-7887
- E-mail: Lorraine.OHara@hcahealthcare.com
-
Chercheur principal:
- James N. Yarnall
-
-
Hawaii
-
Honolulu, Hawaii, États-Unis, 96826
- Recrutement
- Kapiolani Medical Center for Women and Children
-
Contact:
- Site Public Contact
- Numéro de téléphone: 808-983-6090
-
Chercheur principal:
- Wade T. Kyono
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Recrutement
- Lurie Children's Hospital-Chicago
-
Contact:
- Site Public Contact
- Numéro de téléphone: 773-880-4562
-
Chercheur principal:
- Elizabeth A. Sokol
-
Chicago, Illinois, États-Unis, 60637
- Recrutement
- University of Chicago Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Chercheur principal:
- Ami V. Desai
-
Chicago, Illinois, États-Unis, 60612
- Recrutement
- University of Illinois
-
Contact:
- Site Public Contact
- Numéro de téléphone: 312-355-3046
-
Chercheur principal:
- Dipti S. Dighe
-
Oak Lawn, Illinois, États-Unis, 60453
- Recrutement
- Advocate Children's Hospital-Oak Lawn
-
Contact:
- Site Public Contact
- Numéro de téléphone: 847-723-7570
-
Chercheur principal:
- Rebecca E. McFall
-
Park Ridge, Illinois, États-Unis, 60068
- Recrutement
- Advocate Children's Hospital-Park Ridge
-
Contact:
- Site Public Contact
- E-mail: helpdesk@childrensoncologygroup.org
-
Chercheur principal:
- Rebecca E. McFall
-
Peoria, Illinois, États-Unis, 61637
- Recrutement
- OSF Children's Hospital of Illinois
-
Chercheur principal:
- Prerna Kumar
-
Contact:
- Site Public Contact
- Numéro de téléphone: 309-624-4945
- E-mail: ChildrensHospitalofIllinois@osfhealthcare.org
-
Springfield, Illinois, États-Unis, 62702
- Recrutement
- Southern Illinois University School of Medicine
-
Contact:
- Site Public Contact
- Numéro de téléphone: 217-545-7929
-
Chercheur principal:
- Gregory P. Brandt
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Recrutement
- Riley Hospital for Children
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-248-1199
-
Chercheur principal:
- Marissa Just
-
Indianapolis, Indiana, États-Unis, 46260
- Recrutement
- Ascension Saint Vincent Indianapolis Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 317-338-2194
- E-mail: research@stvincent.org
-
Chercheur principal:
- Bassem I. Razzouk
-
-
Iowa
-
Des Moines, Iowa, États-Unis, 50309
- Recrutement
- Blank Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 515-241-8912
- E-mail: samantha.mallory@unitypoint.org
-
Chercheur principal:
- Samantha L. Mallory
-
Iowa City, Iowa, États-Unis, 52242
- Recrutement
- University of Iowa/Holden Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-237-1225
-
Chercheur principal:
- Andrew P. Groves
-
-
Kansas
-
Wichita, Kansas, États-Unis, 67214
- Recrutement
- Wesley Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 316-962-7802
- E-mail: WesleyResearch@wesleymc.com
-
Chercheur principal:
- Nathan S. Hall
-
-
Kentucky
-
Lexington, Kentucky, États-Unis, 40536
- Recrutement
- University of Kentucky/Markey Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 859-257-3379
-
Chercheur principal:
- James T. Badgett
-
Louisville, Kentucky, États-Unis, 40202
- Recrutement
- Norton Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 502-629-5500
- E-mail: CancerResource@nortonhealthcare.org
-
Chercheur principal:
- Michael J. Ferguson
-
-
Louisiana
-
New Orleans, Louisiana, États-Unis, 70118
- Recrutement
- Children's Hospital New Orleans
-
Chercheur principal:
- Maria C. Velez-Yanguas
-
Contact:
- Site Public Contact
- Numéro de téléphone: 504-894-5377
-
-
Maine
-
Bangor, Maine, États-Unis, 04401
- Recrutement
- Eastern Maine Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 207-973-4274
-
Chercheur principal:
- Daniel L. Callaway
-
Scarborough, Maine, États-Unis, 04074
- Recrutement
- Maine Children's Cancer Program
-
Chercheur principal:
- Sei-Gyung K. Sze
-
Contact:
- Site Public Contact
- Numéro de téléphone: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287
- Recrutement
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Chercheur principal:
- Allen R. Chen
-
Contact:
- Site Public Contact
- Numéro de téléphone: 410-955-8804
- E-mail: jhcccro@jhmi.edu
-
Baltimore, Maryland, États-Unis, 21215
- Recrutement
- Sinai Hospital of Baltimore
-
Chercheur principal:
- Jason M. Fixler
-
Contact:
- Site Public Contact
- Numéro de téléphone: 410-601-9083
-
Baltimore, Maryland, États-Unis, 21201
- Recrutement
- University of Maryland/Greenebaum Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-888-8823
-
Chercheur principal:
- Teresa A. York
-
Bethesda, Maryland, États-Unis, 20889-5600
- Recrutement
- Walter Reed National Military Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 301-319-2100
-
Chercheur principal:
- Kip R. Hartman
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Recrutement
- Massachusetts General Hospital Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 877-726-5130
-
Chercheur principal:
- Lauren H. Boal
-
Boston, Massachusetts, États-Unis, 02215
- Recrutement
- Dana-Farber Cancer Institute
-
Contact:
- Site Public Contact
- Numéro de téléphone: 877-442-3324
-
Chercheur principal:
- Suzanne Shusterman
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- Recrutement
- C S Mott Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-865-1125
-
Chercheur principal:
- Rajen Mody
-
Detroit, Michigan, États-Unis, 48201
- Suspendu
- Children's Hospital of Michigan
-
Grand Rapids, Michigan, États-Unis, 49503
- Recrutement
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Chercheur principal:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, États-Unis, 49007
- Recrutement
- Bronson Methodist Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Chercheur principal:
- Kathleen Y. Butler
-
Royal Oak, Michigan, États-Unis, 48073
- Recrutement
- Corewell Health Children's
-
Contact:
- Site Public Contact
- Numéro de téléphone: 248-551-7695
-
Chercheur principal:
- Marie V. Nelson
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55404
- Recrutement
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Chercheur principal:
- Michael K. Richards
-
Contact:
- Site Public Contact
- Numéro de téléphone: 612-813-5913
- E-mail: pauline.mitby@childrensmn.org
-
Minneapolis, Minnesota, États-Unis, 55455
- Recrutement
- University of Minnesota/Masonic Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 612-624-2620
-
Chercheur principal:
- Robin L. Williams
-
Rochester, Minnesota, États-Unis, 55905
- Recrutement
- Mayo Clinic in Rochester
-
Contact:
- Site Public Contact
- Numéro de téléphone: 855-776-0015
-
Chercheur principal:
- Peter Schoettler
-
-
Mississippi
-
Jackson, Mississippi, États-Unis, 39216
- Recrutement
- University of Mississippi Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 601-815-6700
-
Chercheur principal:
- Amanda Strobel
-
-
Missouri
-
Columbia, Missouri, États-Unis, 65212
- Recrutement
- University of Missouri Children's Hospital
-
Chercheur principal:
- Barbara A. Gruner
-
Contact:
- Site Public Contact
- Numéro de téléphone: 573-882-1960
- E-mail: snwq62@health.missouri.edu
-
Kansas City, Missouri, États-Unis, 64108
- Recrutement
- Children's Mercy Hospitals and Clinics
-
Chercheur principal:
- Keith J. August
-
Contact:
- Site Public Contact
- Numéro de téléphone: 816-302-6808
- E-mail: COGResearchGroup@cmh.edu
-
St Louis, Missouri, États-Unis, 63110
- Recrutement
- Washington University School of Medicine
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Chercheur principal:
- Frederick S. Huang
-
St Louis, Missouri, États-Unis, 63141
- Recrutement
- Mercy Hospital Saint Louis
-
Contact:
- Site Public Contact
- Numéro de téléphone: 314-251-7066
-
Chercheur principal:
- Robin D. Hanson
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68114
- Recrutement
- Children's Hospital and Medical Center of Omaha
-
Contact:
- Site Public Contact
- Numéro de téléphone: 402-955-3949
-
Chercheur principal:
- Jill C. Beck
-
Omaha, Nebraska, États-Unis, 68198
- Recrutement
- University of Nebraska Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 402-559-6941
- E-mail: unmcrsa@unmc.edu
-
Chercheur principal:
- Jill C. Beck
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89135
- Recrutement
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Contact:
- Site Public Contact
- Numéro de téléphone: 702-384-0013
- E-mail: research@sncrf.org
-
Chercheur principal:
- Joseph L. Lasky
-
-
New Hampshire
-
Lebanon, New Hampshire, États-Unis, 03756
- Recrutement
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Chercheur principal:
- Angela Ricci
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-639-6918
- E-mail: cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Hackensack, New Jersey, États-Unis, 07601
- Recrutement
- Hackensack University Medical Center
-
Chercheur principal:
- Katharine Offer
-
Contact:
- Site Public Contact
- Numéro de téléphone: 551-996-2897
-
Morristown, New Jersey, États-Unis, 07960
- Recrutement
- Morristown Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 973-971-5900
-
Chercheur principal:
- Kathryn L. Laurie
-
New Brunswick, New Jersey, États-Unis, 08901
- Recrutement
- Saint Peter's University Hospital
-
Chercheur principal:
- Nibal A. Zaghloul
-
Contact:
- Site Public Contact
- Numéro de téléphone: 732-745-8600
- E-mail: officeofresearch@saintpetersuh.com
-
New Brunswick, New Jersey, États-Unis, 08903
- Recrutement
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 732-235-8675
-
Chercheur principal:
- Nehal S. Parikh
-
Newark, New Jersey, États-Unis, 07112
- Recrutement
- Newark Beth Israel Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 973-926-7230
- E-mail: Christine.Kosmides@rwjbh.org
-
Chercheur principal:
- Teena Bhatla
-
Paterson, New Jersey, États-Unis, 07503
- Recrutement
- Saint Joseph's Regional Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 973-754-2207
- E-mail: HallL@sjhmc.org
-
Chercheur principal:
- Alissa Kahn
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis, 87106
- Suspendu
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, États-Unis, 12208
- Recrutement
- Albany Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 518-262-5513
-
Chercheur principal:
- Lauren R. Weintraub
-
Buffalo, New York, États-Unis, 14263
- Recrutement
- Roswell Park Cancer Institute
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-767-9355
- E-mail: askroswell@roswellpark.org
-
Chercheur principal:
- Clare J. Twist
-
Mineola, New York, États-Unis, 11501
- Recrutement
- NYU Langone Hospital - Long Island
-
Contact:
- Site Public Contact
- Numéro de téléphone: 212-263-4432
- E-mail: cancertrials@nyulangone.org
-
Chercheur principal:
- Chana L. Glasser
-
New Hyde Park, New York, États-Unis, 11040
- Recrutement
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
Contact:
- Site Public Contact
- Numéro de téléphone: 718-470-3460
-
Chercheur principal:
- Julie I. Krystal
-
New York, New York, États-Unis, 10032
- Recrutement
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Chercheur principal:
- Nobuko Hijiya
-
Contact:
- Site Public Contact
- Numéro de téléphone: 212-342-5162
- E-mail: cancerclinicaltrials@cumc.columbia.edu
-
New York, New York, États-Unis, 10016
- Recrutement
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Chercheur principal:
- Elizabeth A. Raetz
-
Contact:
- Site Public Contact
- E-mail: CancerTrials@nyulangone.org
-
Rochester, New York, États-Unis, 14642
- Recrutement
- University of Rochester
-
Contact:
- Site Public Contact
- Numéro de téléphone: 585-275-5830
-
Chercheur principal:
- Rafi R. Kazi
-
Syracuse, New York, États-Unis, 13210
- Recrutement
- State University of New York Upstate Medical University
-
Contact:
- Site Public Contact
- Numéro de téléphone: 315-464-5476
-
Chercheur principal:
- Melanie A. Comito
-
The Bronx, New York, États-Unis, 10467
- Recrutement
- Montefiore Medical Center - Moses Campus
-
Contact:
- Site Public Contact
- Numéro de téléphone: 718-379-6866
- E-mail: eskwak@montefiore.org
-
Chercheur principal:
- Alice Lee
-
Valhalla, New York, États-Unis, 10595
- Recrutement
- New York Medical College
-
Contact:
- Site Public Contact
- Numéro de téléphone: 914-594-3794
-
Chercheur principal:
- Andrew J. Bellantoni
-
-
North Carolina
-
Asheville, North Carolina, États-Unis, 28801
- Recrutement
- Mission Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 828-213-7055
- E-mail: NCDV.ResearchRegulatory@HCAHealthcare.com
-
Chercheur principal:
- Douglas J. Scothorn
-
Chapel Hill, North Carolina, États-Unis, 27599
- Recrutement
- UNC Lineberger Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 877-668-0683
- E-mail: cancerclinicaltrials@med.unc.edu
-
Chercheur principal:
- Thomas B. Alexander
-
Charlotte, North Carolina, États-Unis, 28203
- Recrutement
- Carolinas Medical Center/Levine Cancer Institute
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-804-9376
-
Chercheur principal:
- Joel A. Kaplan
-
Charlotte, North Carolina, États-Unis, 28204
- Recrutement
- Novant Health Presbyterian Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 980-201-6360
- E-mail: kashah@novanthealth.org
-
Chercheur principal:
- Holly Edington
-
Durham, North Carolina, États-Unis, 27710
- Recrutement
- Duke University Medical Center
-
Chercheur principal:
- Jessica M. Sun
-
Contact:
- Site Public Contact
- Numéro de téléphone: 888-275-3853
-
Greenville, North Carolina, États-Unis, 27834
- Recrutement
- East Carolina University
-
Contact:
- Site Public Contact
- Numéro de téléphone: 252-744-1015
- E-mail: eubankss@ecu.edu
-
Chercheur principal:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, États-Unis, 27157
- Recrutement
- Wake Forest University Health Sciences
-
Contact:
- Site Public Contact
- Numéro de téléphone: 336-713-6771
-
Chercheur principal:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, États-Unis, 58122
- Recrutement
- Sanford Broadway Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 701-323-5760
- E-mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Chercheur principal:
- Samuel J. Milanovich
-
-
Ohio
-
Akron, Ohio, États-Unis, 44308
- Recrutement
- Children's Hospital Medical Center of Akron
-
Contact:
- Site Public Contact
- Numéro de téléphone: 330-543-3193
-
Chercheur principal:
- Lauren R. Draper
-
Cincinnati, Ohio, États-Unis, 45229
- Recrutement
- Cincinnati Children's Hospital Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 513-636-2799
- E-mail: cancer@cchmc.org
-
Chercheur principal:
- Katherine M. Somers
-
Cleveland, Ohio, États-Unis, 44195
- Recrutement
- Cleveland Clinic Foundation
-
Contact:
- Site Public Contact
- Numéro de téléphone: 866-223-8100
- E-mail: TaussigResearch@ccf.org
-
Chercheur principal:
- Matteo M. Trucco
-
Cleveland, Ohio, États-Unis, 44106
- Recrutement
- Rainbow Babies and Childrens Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 216-844-5437
-
Chercheur principal:
- Duncan S. Stearns
-
Columbus, Ohio, États-Unis, 43205
- Recrutement
- Nationwide Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 614-722-6039
- E-mail: Melinda.Triplet@nationwidechildrens.org
-
Chercheur principal:
- Mark A. Ranalli
-
Dayton, Ohio, États-Unis, 45404
- Recrutement
- Dayton Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-228-4055
-
Chercheur principal:
- Jordan M. Wright
-
Toledo, Ohio, États-Unis, 43606
- Recrutement
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 419-824-1842
- E-mail: PCIOncResearch@promedica.org
-
Chercheur principal:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104
- Recrutement
- University of Oklahoma Health Sciences Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Chercheur principal:
- Rene Y. McNall-Knapp
-
Tulsa, Oklahoma, États-Unis, 74136
- Recrutement
- Saint Francis Children's Hospital
-
Chercheur principal:
- Jill A. Salo
-
Contact:
- Site Public Contact
- Numéro de téléphone: 918-502-6720
-
-
Oregon
-
Portland, Oregon, États-Unis, 97227
- Recrutement
- Legacy Emanuel Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 503-413-2560
-
Chercheur principal:
- Jason M. Glover
-
Portland, Oregon, États-Unis, 97239
- Recrutement
- Oregon Health and Science University
-
Contact:
- Site Public Contact
- Numéro de téléphone: 503-494-1080
- E-mail: trials@ohsu.edu
-
Chercheur principal:
- Susan J. Lindemulder
-
-
Pennsylvania
-
Allentown, Pennsylvania, États-Unis, 18103
- Recrutement
- Lehigh Valley Hospital-Cedar Crest
-
Contact:
- Site Public Contact
- Numéro de téléphone: 610-402-9543
- E-mail: Morgan_M.Horton@lvhn.org
-
Chercheur principal:
- Jacob A. Troutman
-
Danville, Pennsylvania, États-Unis, 17822
- Recrutement
- Geisinger Medical Center
-
Chercheur principal:
- Jagadeesh Ramdas
-
Contact:
- Site Public Contact
- Numéro de téléphone: 570-271-5251
- E-mail: cancerresearch@geisinger.edu
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Recrutement
- Children's Hospital of Philadelphia
-
Chercheur principal:
- Rochelle Bagatell
-
Contact:
- Site Public Contact
- Numéro de téléphone: 267-425-5544
- E-mail: CancerTrials@email.chop.edu
-
Philadelphia, Pennsylvania, États-Unis, 19134
- Recrutement
- Saint Christopher's Hospital for Children
-
Contact:
- Site Public Contact
- Numéro de téléphone: 215-427-8991
-
Chercheur principal:
- Gregory E. Halligan
-
Pittsburgh, Pennsylvania, États-Unis, 15224
- Recrutement
- Children's Hospital of Pittsburgh of UPMC
-
Contact:
- Site Public Contact
- Numéro de téléphone: 412-692-8570
- E-mail: jean.tersak@chp.edu
-
Chercheur principal:
- Jean M. Tersak
-
-
Rhode Island
-
Providence, Rhode Island, États-Unis, 02903
- Recrutement
- Rhode Island Hospital
-
Chercheur principal:
- Bradley DeNardo
-
Contact:
- Site Public Contact
- Numéro de téléphone: 401-444-1488
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29425
- Recrutement
- Medical University of South Carolina
-
Contact:
- Site Public Contact
- Numéro de téléphone: 843-792-9321
- E-mail: hcc-clinical-trials@musc.edu
-
Chercheur principal:
- Jacqueline M. Kraveka
-
Columbia, South Carolina, États-Unis, 29203
- Recrutement
- Prisma Health Richland Hospital
-
Chercheur principal:
- Stuart L. Cramer
-
Contact:
- Site Public Contact
- Numéro de téléphone: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, États-Unis, 29605
- Recrutement
- BI-LO Charities Children's Cancer Center
-
Chercheur principal:
- Aniket Saha
-
Contact:
- Site Public Contact
- Numéro de téléphone: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, États-Unis, 57117-5134
- Recrutement
- Sanford USD Medical Center - Sioux Falls
-
Contact:
- Site Public Contact
- Numéro de téléphone: 605-312-3320
- E-mail: OncologyClinicalTrialsSF@SanfordHealth.org
-
Chercheur principal:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Knoxville, Tennessee, États-Unis, 37916
- Recrutement
- East Tennessee Childrens Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 865-541-8266
-
Chercheur principal:
- Susan E. Spiller
-
Memphis, Tennessee, États-Unis, 38105
- Recrutement
- Saint Jude Children's Research Hospital
-
Chercheur principal:
- Sara M. Federico
-
Contact:
- Site Public Contact
- Numéro de téléphone: 888-226-4343
- E-mail: referralinfo@stjude.org
-
Nashville, Tennessee, États-Unis, 37232
- Recrutement
- Vanderbilt University/Ingram Cancer Center
-
Chercheur principal:
- Daniel J. Benedetti
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-811-8480
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- The Children's Hospital at TriStar Centennial
-
Contact:
- Site Public Contact
- Numéro de téléphone: 615-342-1919
-
Chercheur principal:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, États-Unis, 78723
- Recrutement
- Dell Children's Medical Center of Central Texas
-
Contact:
- Site Public Contact
- Numéro de téléphone: 512-628-1902
- E-mail: TXAUS-DL-SFCHemonc.research@ascension.org
-
Chercheur principal:
- Shannon M. Cohn
-
Corpus Christi, Texas, États-Unis, 78411
- Recrutement
- Driscoll Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 361-694-5311
- E-mail: Crystal.DeLosSantos@dchstx.org
-
Chercheur principal:
- Nkechi I. Mba
-
Dallas, Texas, États-Unis, 75390
- Recrutement
- UT Southwestern/Simmons Cancer Center-Dallas
-
Chercheur principal:
- Tanya C. Watt
-
Contact:
- Site Public Contact
- Numéro de téléphone: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Dallas, Texas, États-Unis, 75230
- Recrutement
- Medical City Dallas Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 972-566-5588
-
Chercheur principal:
- Maurizio L. Ghisoli
-
El Paso, Texas, États-Unis, 79905
- Recrutement
- El Paso Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 915-298-5444
- E-mail: ranjan.bista@ttuhsc.edu
-
Chercheur principal:
- Benjamin Carcamo
-
Fort Worth, Texas, États-Unis, 76104
- Recrutement
- Cook Children's Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 682-885-2103
- E-mail: CookChildrensResearch@cookchildrens.org
-
Chercheur principal:
- Chelsee Greer
-
Houston, Texas, États-Unis, 77030
- Recrutement
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 713-798-1354
- E-mail: burton@bcm.edu
-
Chercheur principal:
- Jennifer H. Foster
-
Houston, Texas, États-Unis, 77030
- Recrutement
- UT MD Anderson Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 866-632-6789
- E-mail: askmdanderson@mdanderson.org
-
Chercheur principal:
- Najat C. Daw
-
Lubbock, Texas, États-Unis, 79410
- Recrutement
- Covenant Children's Hospital
-
Chercheur principal:
- Kishor M. Bhende
-
Contact:
- Site Public Contact
- Numéro de téléphone: 806-725-8657
- E-mail: mbisbee@providence.org
-
Lubbock, Texas, États-Unis, 79415
- Recrutement
- UMC Cancer Center / UMC Health System
-
Contact:
- Site Public Contact
- Numéro de téléphone: 806-775-8590
-
Chercheur principal:
- Erin K. Barr
-
San Antonio, Texas, États-Unis, 78207
- Recrutement
- Children's Hospital of San Antonio
-
Contact:
- Site Public Contact
- Numéro de téléphone: 210-704-2894
- E-mail: bridget.medina@christushealth.org
-
Chercheur principal:
- Julie Voeller
-
San Antonio, Texas, États-Unis, 78229
- Recrutement
- University of Texas Health Science Center at San Antonio
-
Contact:
- Site Public Contact
- Numéro de téléphone: 210-450-3800
- E-mail: phoresearchoffice@uthscsa.edu
-
Chercheur principal:
- Aaron J. Sugalski
-
San Antonio, Texas, États-Unis, 78229
- Recrutement
- Methodist Children's Hospital of South Texas
-
Contact:
- Site Public Contact
- Numéro de téléphone: 210-575-6240
- E-mail: Vinod.GidvaniDiaz@hcahealthcare.com
-
Chercheur principal:
- Jose M. Esquilin
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84113
- Recrutement
- Primary Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 801-585-5270
-
Chercheur principal:
- Leonora R. Slatnick
-
-
Vermont
-
Burlington, Vermont, États-Unis, 05405
- Recrutement
- University of Vermont and State Agricultural College
-
Contact:
- Site Public Contact
- Numéro de téléphone: 802-656-8990
- E-mail: rpo@uvm.edu
-
Chercheur principal:
- Jessica L. Heath
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22908
- Recrutement
- University of Virginia Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 434-243-6303
- E-mail: uvacancertrials@hscmail.mcc.virginia.edu
-
Chercheur principal:
- Brian C. Belyea
-
Portsmouth, Virginia, États-Unis, 23708-2197
- Recrutement
- Naval Medical Center - Portsmouth
-
Contact:
- Site Public Contact
- Numéro de téléphone: 757-953-5939
-
Chercheur principal:
- Karin Brockman
-
-
Washington
-
Seattle, Washington, États-Unis, 98105
- Recrutement
- Seattle Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 866-987-2000
-
Chercheur principal:
- Sarah E. Leary
-
Spokane, Washington, États-Unis, 99204
- Recrutement
- Providence Sacred Heart Medical Center and Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-228-6618
- E-mail: HopeBeginsHere@providence.org
-
Chercheur principal:
- Judy L. Felgenhauer
-
Tacoma, Washington, États-Unis, 98405
- Recrutement
- Mary Bridge Children's Hospital and Health Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 253-403-1461
- E-mail: research@multicare.org
-
Chercheur principal:
- Robert G. Irwin
-
-
West Virginia
-
Huntington, West Virginia, États-Unis, 25701
- Recrutement
- Edwards Comprehensive Cancer Center
-
Chercheur principal:
- Mark A. Ranalli
-
Contact:
- Site Public Contact
- Numéro de téléphone: 304-399-6566
- E-mail: Christina.Cole@chhi.org
-
Morgantown, West Virginia, États-Unis, 26506
- Recrutement
- West Virginia University Healthcare
-
Contact:
- Site Public Contact
- Numéro de téléphone: 304-293-7374
- E-mail: cancertrialsinfo@hsc.wvu.edu
-
Chercheur principal:
- Ashley E. Meyer
-
-
Wisconsin
-
Green Bay, Wisconsin, États-Unis, 54301
- Suspendu
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison, Wisconsin, États-Unis, 53792
- Recrutement
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
-
Chercheur principal:
- Margo L. Hoover-Regan
-
Marshfield, Wisconsin, États-Unis, 54449
- Recrutement
- Marshfield Medical Center-Marshfield
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Chercheur principal:
- Michelle A. Manalang
-
Milwaukee, Wisconsin, États-Unis, 53226
- Recrutement
- Children's Hospital of Wisconsin
-
Chercheur principal:
- Angela Steineck
-
Contact:
- Site Public Contact
- Numéro de téléphone: 414-955-4727
- E-mail: MACCCTO@mcw.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Patients must be enrolled on APEC14B1 and have consented to testing through the Molecular Characterization Initiative (MCI), prior to enrollment on ANBL2131
-
≤ 30 years at the time of initial diagnosis with high-risk disease
-
* Must have a diagnosis of neuroblastoma (NBL) or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamines
-
Newly diagnosed, high risk neuroblastoma (HRNBL) defined as one of the following:
- Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification
- Age ≥ 547 days and INRG stage M regardless of biologic features (clinical MYCN testing not required prior to enrollment)
- Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to stage M without systemic chemotherapy
- Age ≥ 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to stage M without systemic chemotherapy (clinical MYCN testing not required prior to enrollment)
-
-
Patients must have a body surface area (BSA) ≥ 0.25 m^2
-
No prior anti-cancer therapy except as outlined below:
- Patients initially recognized to have high-risk disease treated with topotecan/cyclophosphamide initiated on an emergent basis and within allowed timing, and with consent
- Patients observed or treated with a single cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high-risk disease but subsequently found to meet the criteria
- Patients who received localized emergency radiation to sites of life threatening or function-threatening disease prior to or immediately after establishment of the definitive diagnosis
-
Human immunodeficiency virus (HIV) -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
A serum creatinine based on age/sex as follows:
-
1 month to < 6 months: Male 0.4 mg/dL and female 0.4mg/dL
-
6 months to < 1 year: Male 0.5 mg/dL and female 0.5 mg/dL
-
1 to < 2 years: Male 0.6 mg/dL and female 0.6 mg/dL
-
2 to < 6 years: Male 0.8 mg/dL and female 0.8 mg/dL
-
6 to < 10 years: Male 1 mg/dL and female 1 mg/dL
-
10 to < 13 years: Male 1.2 mg/dL and female 1.2 mg/dL
-
13 to < 16 years: Male 1.5 mg/dL and female 1.4 mg/dL
-
≥ 16 years: Male 1.7 mg/dL and female 1.4 mg/dL
- The threshold creatinine values were derived from the Schwartz formula for estimating glomerular filtration rate (GFR) utilizing child length and stature data published by the Centers for Disease Control (CDC)
-
or a 24-hour urine creatinine clearance ≥ 70 mL/min/1.73 m^2 or
-
or a GFR ≥ 70 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method or direct small molecule clearance method (iothalamate or other molecule per institutional standard)
- Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility
-
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age
-
Serum glutamic pyruvic transaminase (SGPT) (Alanine aminotransferase [ALT]) ≤ 10 x ULN*
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
-
* Shortening fraction of ≥ 27% by echocardiogram, or
- Ejection fraction of ≥ 50% by echocardiogram or radionuclide angiogram
-
Ability to tolerate Peripheral Blood Stem Cell (PBSC) collection:
No known contraindication to PBSC collection. Examples of contraindications might be a weight or size less than the collecting institution finds feasible, or a physical condition that would limit the ability of the child to undergo apheresis catheter placement (if necessary) and/or the apheresis procedure
Exclusion Criteria:
- Patients who are 365-546 days of age with INRG Stage M and MYCN non-amplified NBL, irrespective of additional biologic features
- Patients ≥ 547 days of age with INRG Stage L2, MYCN non-amplified NBL, regardless of additional biologic features
- Patients with known bone marrow failure syndromes
- Patients on chronic immunosuppressive medications (e.g., tacrolimus, cyclosporine, corticosteroids) for reasons other than prevention/treatment of allergic reactions and adrenal replacement therapy are not eligible. Topical and inhaled corticosteroids are acceptable
- Patients with a primary immunodeficiency syndrome who require ongoing immune globulin replacement therapy
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required prior to enrollment for female patients of childbearing potential
- Lactating females who plan to breastfeed their infants
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, food and drug administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Arm A (SOC treatment)
See detailed description |
Given IV
Autres noms:
Given IV
Autres noms:
Given IV
Autres noms:
Undergo bone marrow biopsy
Autres noms:
Given IV
Autres noms:
Given IV
Autres noms:
Undergo MRI
Autres noms:
Undergo ECHO
Autres noms:
Undergo MUGA
Autres noms:
Undergo bone marrow aspiration Given IV
Autres noms:
Undergo CT scan
Autres noms:
Given IV
Autres noms:
Undergo radiation therapy
Autres noms:
Undergo blood and urine sample collection
Autres noms:
Ancillary studies Given IV
Autres noms:
Given IV Given IV
Autres noms:
Given IV
Autres noms:
Undergo FDG PET
Autres noms:
Undergo stem cell infusion
Autres noms:
Given PO
Autres noms:
Undergo apheresis
Autres noms:
Undergo I-MIBG scan
Autres noms:
Given PO or via NG or G tube
Autres noms:
Undergo tumor resection surgery |
|
Expérimental: Arm B (Dinutuximab in induction)
See detailed description |
Given IV
Autres noms:
Given IV
Autres noms:
Given IV
Autres noms:
Undergo bone marrow biopsy
Autres noms:
Given IV
Autres noms:
Given IV
Autres noms:
Undergo MRI
Autres noms:
Undergo ECHO
Autres noms:
Undergo MUGA
Autres noms:
Undergo bone marrow aspiration Given IV
Autres noms:
Undergo CT scan
Autres noms:
Given IV
Autres noms:
Undergo radiation therapy
Autres noms:
Undergo blood and urine sample collection
Autres noms:
Ancillary studies Given IV
Autres noms:
Given IV Given IV
Autres noms:
Given IV
Autres noms:
Undergo FDG PET
Autres noms:
Undergo stem cell infusion
Autres noms:
Given PO
Autres noms:
Undergo apheresis
Autres noms:
Undergo I-MIBG scan
Autres noms:
Given PO or via NG or G tube
Autres noms:
Undergo tumor resection surgery |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Event free survival (EFS)
Délai: Up to 3 years
|
EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred. |
Up to 3 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
End of Induction (EOI) response rate
Délai: From randomization to end of extended Induction, up to 12 months
|
The response rate will be calculated among all evaluable patients at end of Induction. Responders are defined as patients who achieve a >= partial response per the revised 2017 International Neuroblastoma Response Criteria (INRC) |
From randomization to end of extended Induction, up to 12 months
|
|
Overall survival (OS)
Délai: Up to 3 years
|
OS time is calculated from time of randomization to Arms A or B until death, or until last contact if patient is alive. |
Up to 3 years
|
|
Incidence of adverse events
Délai: Up to 2 years
|
The proportion of patients with at least one grade 3 or higher non-hematologic toxicity or grade 4 or higher hematologic toxicity during protocol therapy, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, will be reported. |
Up to 2 years
|
|
GD2 expression
Délai: Up to 12 months
|
Dinutuximab binding to pre-therapy patient tumor samples will be measured and categorized as high or low. |
Up to 12 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Association between tumor and host factors and outcomes
Délai: Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in Arms A and B to evaluate the relationship between tumor and host factors (including tumor ALK and other somatic mutations, copy-number aberrations, gene fusions, gene expression, and pathogenic germline variants) and chemo-immunotherapy during Induction with outcome. |
Up to 10 years
|
|
Circulating biomarkers and markers of minimal residual disease
Délai: Up to 10 years
|
Will be assessed by comparing the proportion of patients with detectable vs. non-detectable tumor markers (including circulating tumor deoxyribonucleic acid, circulating free DNA, circulating tumor cells, and immune function profiling) between Arms A and B during and after induction and post-consolidation therapy using chi-squared tests at each individual time point, and Cochran's Q across time points to determine if there is a consistent difference in proportions between arms across time. In addition, the tumor markers will be analyzed as continuous variables using longitudinal data analysis methodology such as mixed effects models or generalized estimating equations as appropriate. |
Up to 10 years
|
|
Patterns of failure
Délai: Up to 10 years
|
The impact of early or late chemoimmunotherapy during Induction on the probability of the involvement of a specific disease site at first relapse will be evaluated using Fisher's exact test. |
Up to 10 years
|
|
Effect of telomere maintenance mechanisms
Délai: Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in arms A and B to evaluate the relationship between telomere maintenance mechanism and chemoimmunotherapy during Induction with outcome. Patients will be classified into 3 groups by telomere maintenance mechanism (TMM) based on messenger ribonucleic acid expression of TERT and analysis of telomeric DNA C-circles: telomerase (TERT) positive, alternative of lengthening of telomeres (ALT) positive, or no identified TMM. |
Up to 10 years
|
|
Functional and quality of life outcomes
Délai: At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
Will descriptively summarize and compare the total Memorial Symptom Assessment Scale scores, total sub-domain scores, and individual symptom scores between patients randomized to receive dinutuximab during Induction (Arm B) to those of patients randomized to standard Induction (Arm A). |
At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
|
Adequacy of diagnostic biopsy specimens
Délai: At time of tissue collection
|
Will be evaluated by descriptively comparing the successful delineation of histologic classification, MYCN amplification status, and ALK status via the traditional method of obtaining tissue for diagnosis, open surgical biopsy, versus the less invasive percutaneous core needle biopsy. |
At time of tissue collection
|
|
Associations between family-reported adverse social determinants of health and both clinical outcomes and biology
Délai: Up to 10 years
|
Kaplan-Meier curves of EFS and OS will be generated and used to calculate 3-year EFS and OS estimates. Associations between social determinants of health (SDOH) and survival outcomes and time to receipt of dinutuximab will be evaluated with univariate and multivariate Cox proportional hazard models. Log-binomial regression will be used to estimate risk ratios and 95% CI for the occurrence of dinutuximab consent to randomization and therapy receipt by SDOH exposure. Effect modification of outcomes as a function of poverty, stratified by race/ethnicity, will be explored. |
Up to 10 years
|
|
Develop and validate deep learning predictors of Induction response (imaging objective)
Délai: At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
Scans will be given as input to a convolutional neural network trained to predict EOI response. |
At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
|
Compare institutional versus central determination of overall response, individual response components, and PEIR and GEIR determination (imaging objective)
Délai: Up to 10 years
|
Will be assessed by calculating the percentage of patients receiving the same EOI institutional and centrally reviewed determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and PEIR and GEIR. In addition, Cohen's kappa will be calculated to evaluate the concordance in each of these response measures. |
Up to 10 years
|
|
Incidence of late toxicities
Délai: Up to 10 years
|
Will be addressed by calculating the proportion of treated patients with each late effect, including but not limited to impaired organ function, neuropsychiatric toxicity, and secondary malignancy. A 95% confidence interval will be placed on each proportion. |
Up to 10 years
|
|
Reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts
Délai: Up to 10 years
|
The cumulative incidence of local progression (CILP) in patients with complete response of the primary site at EOI and GEIR on this study will be compared to the CILP rate of 11.2±1.8% observed on ANBL0532 using Gray's test. |
Up to 10 years
|
|
Post-transplant complications
Délai: Up to 100 days post-transplant
|
Will be evaluated by calculating the incidence of endothelial injury complications and non-relapse mortality within 100 days of transplant, transplant-associated thrombotic microangiopathy (TA-TMA), severe TA-TMA, and sinusoidal obstruction syndrome (SOS) on Arms A and B and comparing between arms with a chi-squared test. The impact of TA-TMA occurrence on the timing or exclusion of subsequent therapy and interventions utilized to treat the TA-TMA, and associations with outcomes (EFS and OS) will be assessed. |
Up to 100 days post-transplant
|
|
Associations between end of induction (EOI) response and individual response components
Délai: Up to 10 years
|
Log-rank tests will be used to explore the association between EOI response (using both the revised INRC and GEIR/PEIR classification) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS). |
Up to 10 years
|
|
Changes in image-defined risk factors (IDRF)
Délai: Up to 10 years
|
The proportion of patients in the analytic cohort for whom each particular IDRF and also the presence of any IDRF is absent prior to surgical resection will be computed. McNemar's test for paired observations will be applied to determine whether there is a difference in the proportion of each IDRF and any IDRF present before and after initial therapy, and conditional logistic regression will be used to compare between treatment arms A and B. The IDRF status after initial therapy and whether there has been a change from diagnosis will be associated with surgical outcome (complete vs. incomplete resection, presence or absence of surgical complications) using chi-squared tests, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel test. The association of IDRF status with presence or absence of local failure after primary tumor resection will also be evaluated using a chi-squared test, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel. |
Up to 10 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Sara M Federico, Children's Oncology Group
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs
- Tumeurs par type histologique
- Tumeurs, glandulaires et épithéliales
- Tumeurs, neuroépithéliales
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Tumeurs neuroectodermiques, primitives, périphériques
- Tumeurs neuroectodermiques primitives
- Neuroblastome
- Ganglioneuroblastome
- Organisation et administration
- Administration des services de santé
- Acides aminés, peptides et protéines
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Techniques d'investigation
- Thérapeutique
- Techniques de laboratoire clinique
- Techniques et procédures de diagnostic
- Diagnostic
- Procédures chirurgicales, opératoires
- Azoles
- Techniques cytologiques
- Cytodiagnostic
- Rétinoïdes
- Caroténoïdes
- Polyènes
- Alcènes
- Hydrocarbures, acyclique
- Hydrocarbures
- Cyclohexènes
- Cyclohexanes
- Cycloparaffines
- Hydrocarbures, alicyclique
- Hydrocarbures, cyclique
- Terpènes
- Pigments, biologique
- Facteurs biologiques
- Glucides
- Phénomènes physiques
- Camptothécine
- Alcaloïdes
- Podophyllotoxine
- Tétrahydronaphtalènes
- Naphtalenes
- Hydrocarbures aromatiques polycycliques
- Hydrocarbures, aromatique
- Composés polycycliques
- Glucosides
- Glycosides
- Dacarbazine
- Triazènes
- Imidazoles
- Transplantation
- Indoles
- Produits chimiques inorganiques
- Composés de chlore
- Composés d'azote
- Complexes de coordination
- Acides aminés
- Éléments
- Métaux
- Techniques de diagnostic, chirurgicale
- Techniques de chimie, analytique
- Analyse du spectre
- Moutards phosphoramides
- Composés de moutarde d'azote
- Composés moutarde
- Hydrocarbures, halogénés
- Phosphoramides
- Composés organophosphores
- Métaux, lourds
- Alcaloïdes Vinca
- Alcaloïdes de la secologane tryptamine
- Alcaloïdes indole
- Indolizidines
- Indolizines
- Anthracyclines
- Naphtacènes
- Aminoglycosides
- Composés en platine
- Daunorubicine
- Éléments de transition
- Transplantation cellulaire
- Thérapie à base de cellules et de tissus
- Thérapie biologique
- Cytaphérèse
- Élimination des composants sanguins
- Procédures de réduction des leucocytes
- Séparation des cellules
- Phénylalanine
- Acides aminés, aromatique
- Acides aminés, cyclique
- Administration hospitalière
- Administration des établissements de santé
- Triéthylènephosphoramide
- Aziridines
- Azirines
- Procédures chirurgicales urologiques
- Procédures chirurgicales urogénitales
- Témozolomide
- Irinotécan
- Cyclophosphamide
- Melphalan
- Étoposide
- Carboplatine
- Doxorubicine
- Vincristine
- Cisplatine
- Isotrétinoïne
- Thiotépa
- Topotécan
- Citrate de 1,2-diaminocyclohexaneplatine II
- Radiothérapie
- Radiation
- Biopsie
- Manipulation des échantillons
- Spectroscopie de résonance magnétique
- Platine
- dinutuximab
- Transplantation de cellules souches
- Transplantation de cellules souches hématopoïétiques
- Leukaphérèse
- Département de médecine nucléaire, hôpital
- Résection transurétrale de la vessie
Autres numéros d'identification d'étude
- NCI-2023-08530
- U10CA180886 (Subvention/contrat des NIH des États-Unis)
- NCI-2023-08530 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
- ANBL2131 (Autre identifiant: CTEP)
- ANBL2131 (Autre identifiant: Children's Oncology Group)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .